Literature DB >> 12477767

Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component?

W M Gonsalkorale1, C Perrey, V Pravica, P J Whorwell, I V Hutchinson.   

Abstract

BACKGROUND AND AIMS: Inflammation may play a role in the pathogenesis of irritable bowel syndrome in some individuals, such as in those who develop symptoms following a dysenteric illness. Persisting inflammation, resulting from an imbalance of cytokines regulating the inflammatory response, is one possible mechanism. As the elaboration of cytokines is under genetic control, this study was designed to establish whether there might be a genetic predisposition to an altered pattern of anti-inflammatory cytokine production in patients with irritable bowel syndrome.
SUBJECTS: A total of 230 unselected patients with irritable bowel syndrome and 450 healthy, ethnically matched controls were studied.
METHODS: DNA was extracted from peripheral blood leucocytes of subjects. Allele and genotype frequencies were determined for the anti-inflammatory cytokine interleukin 10 at the site (-1082) concerned with production in lymphocytes. Transforming growth factor beta(1) (codons 10 and 25) genotypes were also examined in a smaller group of subjects.
RESULTS: Patients with irritable bowel syndrome had significantly reduced frequencies of the high producer genotype for interleukin 10 than controls (21% v 32%; p=0.003). There was no apparent relationship with any particular bowel habit subtype. Genotypes for transforming growth factor beta(1) were not altered.
CONCLUSIONS: These preliminary results suggest that at least some patients with irritable bowel syndrome may be genetically predisposed to produce lower amounts of the anti-inflammatory cytokine interleukin 10. This lends some support to the hypothesis that there may be an inflammatory or genetic component in some cases of this condition and that further studies in specific irritable bowel syndrome subgroups are justified.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12477767      PMCID: PMC1773523          DOI: 10.1136/gut.52.1.91

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  18 in total

1.  ARMS-PCR methodologies to determine IL-10, TNF-alpha, TNF-beta and TGF-beta 1 gene polymorphisms.

Authors:  C Perrey; S J Turner; V Pravica; W M Howell; I V Hutchinson
Journal:  Transpl Immunol       Date:  1999-06       Impact factor: 1.708

2.  Polymorphic haplotypes of the interleukin-10 5' flanking region determine variable interleukin-10 transcription and are associated with particular phenotypes of juvenile rheumatoid arthritis.

Authors:  E Crawley; R Kay; J Sillibourne; P Patel; I Hutchinson; P Woo
Journal:  Arthritis Rheum       Date:  1999-06

3.  Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome.

Authors:  R C Spiller; D Jenkins; J P Thornley; J M Hebden; T Wright; M Skinner; K R Neal
Journal:  Gut       Date:  2000-12       Impact factor: 23.059

4.  Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients.

Authors:  K R Neal; J Hebden; R Spiller
Journal:  BMJ       Date:  1997-03-15

5.  Interleukin-10-deficient mice develop chronic enterocolitis.

Authors:  R Kühn; J Löhler; D Rennick; K Rajewsky; W Müller
Journal:  Cell       Date:  1993-10-22       Impact factor: 41.582

6.  Terminal ileal mucosal mast cells in irritable bowel syndrome.

Authors:  A P Weston; W L Biddle; P S Bhatia; P B Miner
Journal:  Dig Dis Sci       Date:  1993-09       Impact factor: 3.199

7.  Variation in the TNF-alpha promoter region associated with susceptibility to cerebral malaria.

Authors:  W McGuire; A V Hill; C E Allsopp; B M Greenwood; D Kwiatkowski
Journal:  Nature       Date:  1994-10-06       Impact factor: 49.962

8.  Psychometric scores and persistence of irritable bowel after infectious diarrhoea.

Authors:  K A Gwee; J C Graham; M W McKendrick; S M Collins; J S Marshall; S J Walters; N W Read
Journal:  Lancet       Date:  1996-01-20       Impact factor: 79.321

9.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation.

Authors:  A G Wilson; J A Symons; T L McDowell; H O McDevitt; G W Duff
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Abnormal colonic fermentation in irritable bowel syndrome.

Authors:  T S King; M Elia; J O Hunter
Journal:  Lancet       Date:  1998-10-10       Impact factor: 79.321

View more
  67 in total

Review 1.  Irritable bowel syndrome: methods, mechanisms, and pathophysiology. Genetic epidemiology and pharmacogenetics in irritable bowel syndrome.

Authors:  Michael Camilleri; David A Katzka
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-03-08       Impact factor: 4.052

2.  Findings related to IL-8 and IL-10 gene polymorphisms in a Mexican patient population with irritable bowel syndrome infected with Blastocystis.

Authors:  Angelica Olivo-Diaz; Mirza Romero-Valdovinos; Areli Gudiño-Ramirez; Jesus Reyes-Gordillo; Diego Emiliano Jimenez-Gonzalez; Maria Elena Ramirez-Miranda; Williams Arony Martinez-Flores; Fernando Martinez-Hernandez; Ana Flisser; Pablo Maravilla
Journal:  Parasitol Res       Date:  2012-07       Impact factor: 2.289

Review 3.  Genetic approaches to functional gastrointestinal disorders.

Authors:  Yuri A Saito; Nandita Mitra; Emeran A Mayer
Journal:  Gastroenterology       Date:  2010-02-19       Impact factor: 22.682

4.  T-helper 1, T-helper 2, and T-regulatory cytokines gene polymorphisms in irritable bowel syndrome.

Authors:  Elham Barkhordari; Nima Rezaei; Mahdi Mahmoudi; Pegah Larki; Hamid Reza Ahmadi-Ashtiani; Bita Ansaripour; Maryam Alighardashi; Mohammad Bashashati; Ali Akbar Amirzargar; Naser Ebrahimi-Daryani
Journal:  Inflammation       Date:  2010-10       Impact factor: 4.092

5.  Challenges and prospects for pharmacotherapy in functional gastrointestinal disorders.

Authors:  Gareth J Sanger; Lin Chang; Chas Bountra; Lesley A Houghton
Journal:  Therap Adv Gastroenterol       Date:  2010-09       Impact factor: 4.409

6.  Do Patients with Functional Gastrointestinal Disorders have an Altered Gut Flora?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

Review 7.  Genes and environment in irritable bowel syndrome: one step forward.

Authors:  N J Talley
Journal:  Gut       Date:  2006-12       Impact factor: 23.059

Review 8.  Differential diagnosis between functional and organic intestinal disorders: is there a role for non-invasive tests?

Authors:  Francesco Costa; Maria Gloria Mumolo; Santino Marchi; Massimo Bellini
Journal:  World J Gastroenterol       Date:  2007-01-14       Impact factor: 5.742

Review 9.  Post-infectious irritable bowel syndrome.

Authors:  Andrew W Dupont
Journal:  Curr Gastroenterol Rep       Date:  2007-10

10.  Chronic diarrhea in travelers.

Authors:  Bradley A Connor
Journal:  Curr Infect Dis Rep       Date:  2013-06       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.